|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Simvastatin#Use in Specific Populations]] |
| {{Simvastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use In Specific Populations==
| |
| | |
| ===Pregnancy===
| |
| | |
| '''Pregnancy Category X [See Contraindications (4).]'''
| |
| | |
| ZOCOR is contraindicated in women who are or may become pregnant. Lipid lowering drugs offer no benefit during pregnancy, because [[cholesterol]] and [[cholesterol]] derivatives are needed for normal fetal development. [[Atherosclerosis]] is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary [[hypercholesterolemia]] therapy. There are no adequate and well-controlled studies of use with ZOCOR during pregnancy; however, there are rare reports of congenital anomalies in infants exposed to statins in utero. Animal reproduction studies of simvastatin in rats and rabbits showed no evidence of teratogenicity. Serum [[cholesterol]] and triglycerides increase during normal pregnancy, and [[cholesterol]] or [[cholesterol]] derivatives are essential for fetal development. Because statins decrease [[cholesterol]] synthesis and possibly the synthesis of other biologically active substances derived from [[cholesterol]], ZOCOR may cause fetal harm when administered to a pregnant woman. If ZOCOR is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
| |
| | |
| There are rare reports of congenital anomalies following intrauterine exposure to statins. In a review3 of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or another structurally related [[statin]], the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed those expected in the general population. However, the study was only able to exclude a 3- to 4-fold increased risk of congenital anomalies over the background rate. In 89% of these cases, drug treatment was initiated prior to pregnancy and was discontinued during the first trimester when pregnancy was identified.
| |
| | |
| Simvastatin was not teratogenic in rats or rabbits at doses (25, 10 mg/kg/day, respectively) that resulted in 3 times the human exposure based on mg/m2 surface area. However, in studies with another structurally-related statin, skeletal malformations were observed in rats and mice. | |
| | |
| Women of childbearing potential, who require treatment with ZOCOR for a lipid disorder, should be advised to use effective contraception. For women trying to conceive, discontinuation of ZOCOR should be considered. If pregnancy occurs, ZOCOR should be immediately discontinued.
| |
| | |
| <sup>3</sup>
| |
| <SMALL><SMALL><SMALL>Manson, J.M., Freyssinges, C., Ducrocq, M.B., Stephenson, W.P., Postmarketing Surveillance of Lovastatin and Simvastatin Exposure During Pregnancy, Reproductive Toxicology, 10(6):439-446, 1996.</SMALL></SMALL></SMALL>
| |
| | |
| ===Nursing Mothers===
| |
| | |
| It is not known whether simvastatin is excreted in human milk. Because a small amount of another drug in this class is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women taking simvastatin should not nurse their infants. A decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother [see Contraindications (4)].
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness of simvastatin in patients 10-17 years of age with heterozygous familial [[hypercholesterolemia]] have been evaluated in a controlled clinical trial in adolescent boys and in girls who were at least 1 year post-menarche. Patients treated with simvastatin had an adverse reaction profile similar to that of patients treated with placebo. Doses greater than 40 mg have not been studied in this population. In this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls. [See Dosage and Administration (2.5), Adverse Reactions (6.1), Clinical Studies (14.2).]Adolescent females should be counseled on appropriate contraceptive methods while on simvastatin therapy [see Contraindications (4) and Use in Specific Populations (8.1)]. Simvastatin has not been studied in patients younger than 10 years of age, nor in pre-menarchal girls.
| |
| | |
| ===Geriatric Use===
| |
| | |
| Of the 2,423 patients who received ZOCOR in Phase III clinical studies and the 10,269 patients in the Heart Protection Study who received ZOCOR, 363 (15%) and 5,366 (52%), respectively were ≥65 years old. In HPS, 615 (6%) were ≥75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Since advanced age (≥65 years) is a predisposing factor for myopathy, ZOCOR should be prescribed with caution in the elderly. [See Clinical Pharmacology (12.3).]
| |
| | |
| A pharmacokinetic study with simvastatin showed the mean plasma level of statin activity to be approximately 45% higher in elderly patients between 70-78 years of age compared with patients between 18-30 years of age. In 4S, 1,021 (23%) of 4,444 patients were 65 or older. Lipid-lowering efficacy was at least as great in elderly patients compared with younger patients, and ZOCOR significantly reduced total mortality and CHD mortality in elderly patients with a history of CHD. In HPS, 52% of patients were elderly (4,891 patients 65-69 years and 5,806 patients 70 years or older). The relative risk reductions of CHD death, non-fatal MI, coronary and non-coronary revascularization procedures, and stroke were similar in older and younger patients [see Clinical Studies (14.1)]. In HPS, among 32,145 patients entering the active run-in period, there were 2 cases of [[myopathy]]/[[rhabdomyolysis]]; these patients were aged 67 and 73. Of the 7 cases of [[myopathy]]/[[rhabdomyolysis]] among 10,269 patients allocated to simvastatin, 4 were aged 65 or more (at baseline), of whom one was over 75. There were no overall differences in safety between older and younger patients in either 4S or HPS.
| |
| | |
| Because advanced age (≥65 years) is a predisposing factor for [[myopathy]], including [[[[rhabdomyolysis]]]], ZOCOR should be prescribed with caution in the elderly. In a clinical trial of patients treated with simvastatin 80 mg/day, patients ≥65 years of age had an increased risk of [[myopathy]], including [[rhabdomyolysis]], compared to patients <65 years of age. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]
| |
| | |
| ===Renal Impairment===
| |
| | |
| Caution should be exercised when ZOCOR is administered to patients with severe renal impairment. [See Dosage and Administration (2.6).]
| |
| | |
| ===Hepatic Impairment===
| |
| | |
| ZOCOR is contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels [see Contraindications (4) and Warnings and Precautions (5.2)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZOCOR (SIMVASTATIN) TABLET, FILM COATED [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fdbfe194-b845-42c5-bb87-a48118bc72e7 | publisher = | date = | accessdate = 18 February 2014 }}</ref></div>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Statins}}
| |
| {{Merck&Co}}
| |
|
| |
|
| [[Category:Alcohols]] | | [[Category:Alcohols]] |